We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

187 hedge funds and large institutions have $1.49B invested in Array Biopharma Inc in 2017 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 62 increasing their positions, 61 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 21

12% more funds holding

Funds holding: 167 → 187 (+20)

6% more capital invested

Capital invested by funds: $1.41B → $1.49B (+$82.4M)

10% more call options, than puts

Call options by funds: $30.6M | Put options by funds: $27.9M

2% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 61

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
187
Holders Change
+20
Holders Change %
+11.98%
% of All Funds
4.66%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
48
Increased
62
Reduced
61
Closed
21
Calls
$30.6M
Puts
$27.9M
Net Calls
+$2.74M
Net Calls Change
-$2.54M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$137M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$65.5M
3
Millennium Management
Millennium Management
New York
+$49.4M
4
ACA
Avoro Capital Advisors
New York
+$38.5M
5
Two Sigma Investments
Two Sigma Investments
New York
+$24.3M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$41M
2
Morgan Stanley
Morgan Stanley
New York
-$28.9M
3
BI
BVF Inc
California
-$23.7M
4
O
OrbiMed
New York
-$20.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$208M -$16.2M -1,524,300 -6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$152M +$65.5M +6,156,120 +57%
O
3
OrbiMed
New York
$127M -$20.3M -1,905,900 -12%
BlackRock
4
BlackRock
New York
$115M +$137M +12,835,602 +38,275%
RG
5
Redmile Group
California
$114M -$41M -3,852,914 -23%
State Street
6
State Street
Massachusetts
$73.9M +$19.5M +1,837,047 +29%
Millennium Management
7
Millennium Management
New York
$58.1M +$49.4M +4,642,648 +251%
Franklin Resources
8
Franklin Resources
California
$53.9M +$4.83M +454,066 +8%
ACA
9
Avoro Capital Advisors
New York
$33.8M +$38.5M +3,620,000 +2,263%
PA
10
Pinnacle Associates
New York
$27.4M -$1.55M -145,930 -5%
Invesco
11
Invesco
Georgia
$26.4M +$10.9M +1,023,891 +53%
BI
12
BVF Inc
California
$24.7M -$23.7M -2,223,100 -45%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$23.5M +$799K +75,100 +3%
Two Sigma Investments
14
Two Sigma Investments
New York
$20.4M +$24.3M +2,282,600 New
BIM
15
Bogle Investment Management
Massachusetts
$17.8M -$828K -77,800 -4%
PC
16
PointState Capital
New York
$17.7M +$21.1M +1,983,800 New
Northern Trust
17
Northern Trust
Illinois
$17.6M +$147K +13,840 +0.7%
CI
18
Cambiar Investors
Colorado
$17.5M +$12.3M +1,160,516 +145%
Deutsche Bank
19
Deutsche Bank
Germany
$15.5M -$14.4M -1,355,008 -44%
BBA
20
Baker Bros. Advisors
New York
$14.2M -$10.6M -1,000,000 -39%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$14M +$1.21M +113,632 +8%
CCM
22
Consonance Capital Management
New York
$12.3M -$14.4M -1,350,000 -50%
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$11.4M -$3.11M -292,741 -19%
PAM
24
Panagora Asset Management
Massachusetts
$11.4M +$138K +13,001 +1%
DM
25
Deerfield Management
New York
$10.2M -$5.4M -507,256 -31%
1
2 3 4 5

ARRY Hedge Fund Activity: Q1 2017 in Review

187 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2017, worth a combined $1.49B — up 5.9% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ARRY positions and 21 closed out — a net gain of 27 holders — while 62 added to existing stakes and 61 trimmed.

The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Redmile Group, cutting an estimated $41M.

  • 187 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2017, up from 167 in Q4 2016.
  • Funds reported $1.49B of Array Biopharma Inc stock for Q1 2017, up 5.9% quarter-over-quarter.
  • 48 funds opened new Array Biopharma Inc positions in Q1 2017 and 21 closed out, a net change of +27 holders.
  • The largest Array Biopharma Inc buyer in Q1 2017 was BlackRock, an estimated $137M added.
  • The largest Array Biopharma Inc seller in Q1 2017 was Redmile Group, an estimated $41M sold.

Based on aggregated 13F filings for Q1 2017.